Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sierra Oncology Inc (SRRA)

Sierra Oncology Inc (SRRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application...

SRRA : 54.99 (+0.04%)
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the...

SRRA : 54.99 (+0.04%)
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the...

SRRA : 54.99 (+0.04%)
Sierra Oncology Reports First Quarter 2022 Results

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results...

SRRA : 54.99 (+0.04%)
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to twelve new employees as approved by the...

SRRA : 54.99 (+0.04%)
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline...

SRRA : 54.99 (+0.04%)
GSK : 33.96 (+0.77%)
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA

Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will...

SRRA : 54.99 (+0.04%)
GSK : 33.96 (+0.77%)
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline...

SRRA : 54.99 (+0.04%)
GSK : 33.96 (+0.77%)
RayzeBio Appoints Angie You, Ph.D., to its Board of Directors

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Angie You, Ph.D., to its board of directors. Dr. You is a seasoned...

SRRA : 54.99 (+0.04%)
Huge Takeover Premiums in Play as Another High-Profile Bid Causes Shockwaves to the Market

USA News Group – Once again Elon Musk has sent shockwaves with a tweet. This time Musk announced a “best and final” all-cash offer to buy 100% of Twitter Inc. (NYSE:TWTR) for $43 billion, paying...

PQEFF : 0.0008 (+700.00%)
UNIT : 6.11 (+3.56%)
BAM.TO : 77.50 (-0.18%)
BX : 199.05 (+2.60%)
SRRA : 54.99 (+0.04%)
GSK : 33.96 (+0.77%)
TWTR : 53.70 (+0.66%)
TSLA : 352.56 (+3.80%)

Barchart Exclusives

Insiders Are Buying the Dip in This Semiconductor Stock, Should You?
The company's veteran tech executive just bought shares outright for the first time ever. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar